We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EuropaBio Urges Clearer Policy on Specificities of Biosimilars
EuropaBio Urges Clearer Policy on Specificities of Biosimilars
European biotech companies are calling on the European Commission to address inconsistencies in the labeling and naming of biosimilars as a way to enhance monitoring and acceptance of the rapidly growing product sector.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor